The Technical Analyst
Aquestive Therapeutics [AQST]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Aquestive Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.43% $3.38
America/New_York / 7 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 287.97 mill |
| EPS: | -0.130 |
| P/E: | -26.00 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 85.20 mill |
| Avg Daily Volume: | 2.88 mill |
| RATING 2024-05-07 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -26.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.54x |
| Company: PE -26.00 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.02 - 3.74 ( +/- 10.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Jenkins Abigail L. | Sell | 0 | Common Stock |
| 2024-03-15 | Schobel Alexander Mark | Sell | 50 000 | Common Stock |
| 2024-03-09 | Barber Daniel | Sell | 37 938 | Common Stock |
| 2024-03-09 | Boyd Peter E. | Sell | 8 370 | Common Stock |
| 2024-03-09 | Braender Lori J | Sell | 10 530 | Common Stock |
| INSIDER POWER |
|---|
| 89.68 |
| Last 98 transactions |
| Buy: 6 495 786 | Sell: 225 172 |
Forecast:
16:00 - $3.40
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.40
Forecast 2: 16:00 - $3.40
Forecast 3: 16:00 - $3.40
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.38 (-3.43% ) |
| Volume | 1.425 mill |
| Avg. Vol. | 2.88 mill |
| % of Avg. Vol | 49.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AQST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.67 | N/A | Active |
|---|
AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Latest Press Releases
2024-05-07 16:19:00 - Press Release
Aquestive Therapeutics Reports First Quarter 2024 Financial Results And Provides Business Update
Warren, n.j., may 07, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq:aqst), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, reported financial results for the first quarter, which ended march 31, 2024, and provided an update on recent developments in its business.
2024-04-12 16:01:00 - Press Release
Aquestive Therapeutics To Present Crossover Study Data For Libervant™ (diazepam) Buccal Film At 76th Annual Meeting Of The American Academy Of Neurology
Warren, n.j., april 12, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (the “company” or “aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the company's product candidate, libervant™ (diazepam) buccal film for treatment of children with epilepsy aged two to five, will be presented at the 76th annual meeting of the american academy of neurology (aan) in denver from april 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
2024-03-25 08:00:00 - Press Release
Aquestive Therapeutics Announces Closing Of Underwritten Public Offering Of Common Stock
Warren, n.j., march 25, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive” or the “company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share. at closing, the aggregate gross proceeds of the offering to aquestive, before deducting underwriting discounts and commissions and other offering expenses paid by aquestive, were approximately $75.0 million.
2024-03-19 21:49:00 - Press Release
Aquestive Therapeutics Announces Pricing Of $75 Million Underwritten Public Offering Of Common Stock
Warren, n.j., march 19, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive” or the “company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. the gross proceeds of the offering to aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by aquestive, are expected to be approximately $75.0 million. the company intends to use the net proceeds received from the offering, together with the company's existing cash and cash equivalents, primarily to advance the development and commercialization of its product pipeline, including anaphylm™ (epinephrine) sublingual film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and libervant™ (diazepam) buccal film for the treatment of seizure clusters in epilepsy patients aged two to five, and for working capital, capital expenditures and general corporate purposes...
2024-03-19 16:01:00 - Press Release
Aquestive Therapeutics Announces Proposed Public Offering Of Common Stock
Warren, n.j., march 19, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (the “company” or “aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. in addition, aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. all of the securities in the public offering are being offered by aquestive. the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Latest News
2024-05-07 20:01:29 - Zacks Investment Research
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-05-07 18:26:13 - Zacks Investment Research
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.11 per share a year ago.
2024-04-12 16:01:00 - GlobeNewsWire
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company's product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
2024-04-09 01:25:13 - Seeking Alpha
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
2024-04-02 19:21:20 - Zacks Investment Research
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
2024-03-22 19:06:10 - Zacks Investment Research
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.
2024-03-20 08:46:34 - InvestorPlace
Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today?
Aquestive Therapeutics (NASDAQ: AQST ) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares. Aquestive Therapeutics is selling 16,666,667 shares of AQST stock for $4.50 each in this public offering.
2024-03-18 12:51:07 - Zacks Investment Research
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
2024-03-18 07:51:04 - Zacks Investment Research
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2024-03-05 19:16:10 - Zacks Investment Research
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.23 per share a year ago.